Skip to content
Staging environment — review version. Do not share.

Research and InnovationResearch Radar

MDMA-assisted therapy shows promise for patients from diverse backgrounds

Several sessions of MDMA-assisted therapy led to improvements in a diverse population of adults with post-traumatic stress disorder...

By João L. de Quevedo, MD, PhD

Published on · Last reviewed on · 2 min read

Several sessions of MDMA-assisted therapy led to improvements in a diverse population of adults with moderate to severe post-traumatic stress disorder (PTSD), according to a report in Nature Medicine.

“In a historic first, to our knowledge, for psychedelic treatment studies, participants who identified as ethnically or racially diverse comprised approximately half of the study sample,” wrote Jennifer Mitchell, Ph.D., of the University of California, San Francisco, and colleagues. “A substantial proportion of participants had comorbid features associated with high treatment resistance, such as severe depression, multiple sources of trauma (including childhood and combat trauma), and the dissociative subtype of PTSD.”

Mitchell and colleagues enrolled 104 adults aged 18 or older with moderate to severe PTSD—defined as a score of at least 28 on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The participants, recruited at 13 sites in the United States and Israel, included 28 individuals who identified as Hispanic/Latino and 35 individuals who identified as American Indian/Alaska Native, Asian, Black/African American, Native Hawaiian/Pacific Islander, or multiracial.

Before starting therapy, all participants received three 90-minute therapy sessions to prepare them for the study. Participants were then randomized to receive MDMA combined with therapy or placebo combined with therapy. They completed three eight-hour dosing sessions led by a two-person therapy team, spaced about one month apart. During these therapy sessions, 53 participants took their assigned MDMA pill and 51 took a placebo pill.

At baseline, the mean CAPS-5 score among participants was 39. At 18 weeks (about six to eight weeks after the third dosing session), CAPS-5 scores had fallen by 23.7 points in the MDMA group compared with 14.8 points in the placebo group. In addition, 71.2% of those in the MDMA group no longer met DSM-5 criteria for PTSD after 18 weeks, compared with 47.6% of those in the placebo group. Participants in the MDMA group also showed reductions in functional impairment, as measured by changes from baseline on the Sheehan Disability Scale.

“These findings represent the culmination of more than two decades of research and, together with MAPP1 [an earlier phase 3 trial], indicate that further investigation of this treatment in individuals with moderate to severe PTSD is warranted,” Mitchell and colleagues concluded.

Related content

Mood Disorders

Understanding the complexity of catatonia

Catatonia, a perplexing neuropsychiatric condition, often remains poorly understood despite its profound impact on...

· Explainer